SUPX vs AIXI vs BBAI vs GFAI vs AI

For growth investors, C3.

ai, Inc. (AI) is the stronger pick with 25. 3% revenue growth year-over-year, versus -52. 7% for Super X AI Technology Ltd (SUPX). Analysts rate BigBear. ai Holdings, Inc. (BBAI) a "Hold" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Super X AI Technology Ltd (SUPX) delivered a total return of -36.

0%, compared to -99. 5% for Guardforce AI Co. , Limited (GFAI). Over 10 years, the gap is even starker: SUPX returned -36. 0% versus GFAI's -99. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Xiao-I Corporation (AIXI) is the lower-risk stock at 0.

71β versus BigBear. ai Holdings, Inc. 's 3. 31β — meaning BBAI is approximately 367% more volatile than AIXI relative to the S&P 500. On balance sheet safety, C3. ai, Inc. (AI) carries a lower debt/equity ratio of 1% versus 8% for Guardforce AI Co. , Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), C3.

ai, Inc. (AI) is pulling ahead at 25. 3% versus -52. 7% for Super X AI Technology Ltd (SUPX). On earnings-per-share growth, the picture is similar: Guardforce AI Co. , Limited grew EPS 88. 3% year-over-year, compared to 4. 3% for C3. ai, Inc.. Over a 3-year CAGR, AIXI leads at 29. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Guardforce AI Co.

, Limited (GFAI) is the more profitable company, earning -16. 1% net margin versus -230. 2% for BigBear. ai Holdings, Inc. — meaning it keeps -16. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AIXI leads at -18. 3% versus -83. 4% for AI. At the gross margin level — before operating expenses — AIXI leads at 68. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Xiao-I Corporation (AIXI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

71)). Guardforce AI Co. , Limited (GFAI) carries a higher beta of 2. 36 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AIXI: -98. 8%, GFAI: -99. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (SUPX (Technology) and AIXI (Technology) and BBAI (Technology) and GFAI (Industrials) and AI (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: SUPX is a small-cap quality compounder stock; AIXI is a small-cap high-growth stock; BBAI is a mid-cap quality compounder stock; GFAI is a small-cap quality compounder stock; AI is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.